Constellation Pharmaceuticals Stock Forecast, Price & News

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Constellation Pharmaceuticals in the last year. There are currently 9 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Constellation Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CNST, but not buy additional shares or sell existing shares.
View analyst ratings for Constellation Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Constellation Pharmaceuticals a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Constellation Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Constellation Pharmaceuticals saw a decline in short interest in June. As of June 15th, there was short interest totaling 3,520,000 shares, a decline of 53.7% from the May 31st total of 7,600,000 shares. Based on an average daily volume of 1,340,000 shares, the days-to-cover ratio is presently 2.6 days. Approximately 9.4% of the shares of the stock are short sold.
View Constellation Pharmaceuticals' Short Interest.

Constellation Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Constellation Pharmaceuticals.

Constellation Pharmaceuticals, Inc. (NASDAQ:CNST) released its quarterly earnings results on Sunday, May, 9th. The company reported ($0.84) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.79) by $0.05.
View Constellation Pharmaceuticals' earnings history.

Constellation Pharmaceuticals' stock was trading at $32.57 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CNST stock has increased by 4.4% and is now trading at $33.99.
View which stocks have been most impacted by COVID-19.

11 analysts have issued 1 year price objectives for Constellation Pharmaceuticals' shares. Their forecasts range from $20.00 to $50.00. On average, they expect Constellation Pharmaceuticals' share price to reach $34.14 in the next twelve months. This suggests a possible upside of 0.4% from the stock's current price.
View analysts' price targets for Constellation Pharmaceuticals or view top-rated stocks among Wall Street analysts.

10 employees have rated Constellation Pharmaceuticals CEO Jigar Raythatha on Glassdoor.com. Jigar Raythatha has an approval rating of 100% among Constellation Pharmaceuticals' employees. This puts Jigar Raythatha in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Constellation Pharmaceuticals include Perrigo (PRGO), Legend Biotech (LEGN), Ascendis Pharma A/S (ASND), I-Mab (IMAB), Sarepta Therapeutics (SRPT), Ultragenyx Pharmaceutical (RARE), Apellis Pharmaceuticals (APLS), Arvinas (ARVN), Ionis Pharmaceuticals (IONS), TG Therapeutics (TGTX), Blueprint Medicines (BPMC), Schrödinger (SDGR), Reata Pharmaceuticals (RETA), Hypera (HYPMY) and Allakos (ALLK).
View all of CNST's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Constellation Pharmaceuticals investors own include Advanced Micro Devices (AMD), AbbVie (ABBV), Applied Materials (AMAT), Inovio Pharmaceuticals (INO), Intel (INTC), NVIDIA (NVDA), Pfizer (PFE), Sorrento Therapeutics (SRNE), Cisco Systems (CSCO) and AT&T (T).

(CNST) raised $80 million in an initial public offering (IPO) on Thursday, July 19th 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Jefferies and BMO Capital Markets served as the underwriters for the IPO and Oppenheimer was co-manager.

Constellation Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNST."

Constellation Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Havens Advisors LLC (0.14%). Company insiders that own Constellation Pharmaceuticals stock include Adrian Senderowicz, Anthony B Evnin, Emma Reeve, Group L P Column, James E Audia, Karen Valentine, Mark A Goldsmith, Of The University Of C Regents and Patrick Trojer.
View institutional ownership trends for Constellation Pharmaceuticals.

CNST stock was bought by a variety of institutional investors in the last quarter, including Havens Advisors LLC. Company insiders that have bought Constellation Pharmaceuticals stock in the last two years include Anthony B Evnin, and Group L P Column.
View insider buying and selling activity for Constellation Pharmaceuticals or or view top insider-buying stocks.

Shares of CNST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CNST stock can currently be purchased for approximately $33.99.

Constellation Pharmaceuticals has a market capitalization of $1.63 billion. The company earns $-126,360,000.00 in net income (profit) each year or ($2.81) on an earnings per share basis.

Constellation Pharmaceuticals employs 154 workers across the globe.

The official website for Constellation Pharmaceuticals is www.constellationpharma.com.

Constellation Pharmaceuticals is headquartered at 215 FIRST STREET SUITE 200, CAMBRIDGE MA, 02142.

Constellation Pharmaceuticals' mailing address is 215 FIRST STREET SUITE 200, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-714-0555 or via email at [email protected]